“Improving the bioavailability and solubility of modern APIs remains one of the most persistent hurdles in drug development. As pipelines continue to shift toward highly lipophilic, poorly water-soluble molecules – particularly BCS Class II and IV compounds – formulators are turning to advanced materials, predictive tools, and mechanistic design approaches to ensure adequate bioavailability and therapeutic performance.
“Advances in automation and technology, such as small-scale preparative techniques of solid forms and formulation screening strategies, coupled with evaluation of performance through automated online platforms, is imperative for success in early development. Using these in parallel to one another enables the measurement of critical solubility and dissolution properties, confronting potential developability issues earlier on, saving substantial time and resources.”
Learn more by reading this article in Drug Development & Delivery. Veranova’s VP and General Manager of Cambridge, Dr Craig Grant, discusses how the attributes of a molecule, such as crystallinity, pKa/LogP, melting point, and understanding particle characteristics help to identify viable development and formulation routes early in the screening process.
Read full DD&D article
